Please login to the form below

Not currently logged in
Email:
Password:

Valeant acquires AB Sanitas

Canada-based Valeant Pharmaceuticals International is to acquire Lithuanian speciality pharmaceutical company AB Sanitas in a two-stage deal worth €314m

Canada-based Valeant Pharmaceuticals International is to acquire Lithuanian speciality pharmaceutical company AB Sanitas in a two-stage deal worth €314m.

AB Sanitas sells about 390 generic products in nine Central and Eastern European countries. Its largest markets are Poland, Russia and Lithuania.

Valeant said the major shareholders of AB Sanitas have agreed to sell an 87 per cent stake in the company. That portion of the deal is expected to close during the third quarter, and Valeant said it will then start an offer for the remaining shares.

The Ontario-based company expects to assume €50m ($70.3m) in debt as part of the deal. The acquisition is expected to close during the fourth quarter of 2011.

AB Sanitas is based in Kaunas and develops its own dermatology, ophthalmology and hospital injectable drugs.

26th May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Can involving patients in design transform the clinical trial experience?
While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...

Infographics